Study · Randomized controlled trial · 2020

12 results

Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM.

Ali AM, Mari A, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M

The Journal of clinical endocrinology and metabolism1 Oct 2020Cited by 10 (Europe PMC)

PMID32745202DOI10.1210/clinem/dgaa494PepBankPUB-32745202

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In poorly controlled adults with type 2 diabetes, liraglutide alone significantly lowered HbA1c after 16 weeks.
In plain wordsIn adults with type 2 diabetes, liraglutide alone lowered HbA1c, a measure of blood sugar control, after 16 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change after 16 weeks
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Both liraglutide and canagliflozin significantly lowered HbA1c
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
Report a problemFND-3274520201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide alone increased insulin secretion during the oral glucose tolerance test after 16 weeks.
In plain wordsIn adults with type 2 diabetes, liraglutide alone increased the body's insulin release after a sugar drink.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion during OGTT, (ΔC-Pep/ΔG)0-120
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Insulin secretion during the OGTT, measured with (∆C-Pep/∆G)0-120, increased in the 3 groups (from 0.30 ± 0.06 to 0.48 ± 0.10; 0.29 ± 0.05 to 0.98 ± 0.23; and 0.24 ± 0.06 to 1.09 ± 0.12 in subjects receiving CANA, LIRA and CANA/LIRA respectively
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
Report a problemFND-3274520203
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide alone increased beta cell glucose sensitivity after 16 weeks.
In plain wordsIn adults with type 2 diabetes, liraglutide alone made insulin-producing cells respond better to glucose.
Peptide
Liraglutide
Outcome
IncreaseBeta cell glucose sensitivity
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
an increase in beta cell glucose sensitivity (29 ± 5 to 55 ± 11; 33 ± 6 to 101 ± 16; and 28 ± 6 to 112 ± 12, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
Report a problemFND-3274520204
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the increase in insulin secretion was greater with liraglutide than with canagliflozin.
In plain wordsIn adults with type 2 diabetes, liraglutide increased insulin release more than canagliflozin did.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion, liraglutide versus canagliflozin
Study
n: not reported in source
Comparator
Canagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
Insulin secretion during the OGTT, measured with (∆C-Pep/∆G)0-120, increased in the 3 groups (from 0.30 ± 0.06 to 0.48 ± 0.10; 0.29 ± 0.05 to 0.98 ± 0.23; and 0.24 ± 0.06 to 1.09 ± 0.12 in subjects receiving CANA, LIRA and CANA/LIRA respectively
2 context sentences(design, population, supporting numbers)
Summary · context
P = 0.02 for CANA vs LIRA
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
Report a problemFND-3274520205
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the increase in beta cell glucose sensitivity was greater with liraglutide than with canagliflozin.
In plain wordsIn adults with type 2 diabetes, liraglutide improved beta cell glucose sensitivity more than canagliflozin did.
Peptide
Liraglutide
Outcome
IncreaseBeta cell glucose sensitivity, liraglutide versus canagliflozin
Study
n: not reported in source
Comparator
Canagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Source sentences
Summary
an increase in beta cell glucose sensitivity (29 ± 5 to 55 ± 11; 33 ± 6 to 101 ± 16; and 28 ± 6 to 112 ± 12, respectively
2 context sentences(design, population, supporting numbers)
Summary · context
P = 0.01 for CANA vs LIRA
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
Report a problemFND-3274520206

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In adults with type 2 diabetes treated with the three regimens, the decrease in HbA1c correlated inversely with the increase in beta cell glucose sensitivity.
In plain wordsIn adults with type 2 diabetes, a bigger rise in beta cell glucose sensitivity went with a bigger HbA1c fall across the treatments.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of HbA1c decrease with beta cell glucose sensitivity increase
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Measurements
correlation r
0.71
HbA1c decrease vs beta cell glucose sensitivity increase
Source sentences
Summary
The decrease in HbA1c strongly and inversely correlated with the increase in beta cell glucose sensitivity (r = 0.71, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520211
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, canagliflozin plus liraglutide had no significant additive effect on HbA1c compared with each agent alone.
In plain wordsIn adults with type 2 diabetes, adding canagliflozin to liraglutide did not lower HbA1c more than each drug alone.
Peptide
Liraglutide
Outcome
No significant changeHbA1c, canagliflozin plus liraglutide versus each agent alone
Study
n: not reported in source
Comparator
Liraglutide alone and canagliflozin alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
with no significant additive effect of the combination on HbA1c
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520202
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, canagliflozin plus liraglutide increased insulin secretion during the oral glucose tolerance test from baseline.
In plain wordsIn adults with type 2 diabetes, the canagliflozin and liraglutide combination increased insulin release after a sugar drink.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion with canagliflozin plus liraglutide
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Insulin secretion during the OGTT, measured with (∆C-Pep/∆G)0-120, increased in the 3 groups (from 0.30 ± 0.06 to 0.48 ± 0.10; 0.29 ± 0.05 to 0.98 ± 0.23; and 0.24 ± 0.06 to 1.09 ± 0.12 in subjects receiving CANA, LIRA and CANA/LIRA respectively
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520207
09HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, canagliflozin plus liraglutide increased beta cell glucose sensitivity from baseline.
In plain wordsIn adults with type 2 diabetes, the canagliflozin and liraglutide combination improved beta cell glucose sensitivity.
Peptide
Liraglutide
Outcome
IncreaseBeta cell glucose sensitivity with canagliflozin plus liraglutide
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
an increase in beta cell glucose sensitivity (29 ± 5 to 55 ± 11; 33 ± 6 to 101 ± 16; and 28 ± 6 to 112 ± 12, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520208
10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, canagliflozin plus liraglutide did not increase insulin secretion more than liraglutide alone.
In plain wordsIn adults with type 2 diabetes, adding canagliflozin to liraglutide did not raise insulin release more than liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeInsulin secretion, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
No significant difference in the increase in insulin secretion or beta cell glucose sensitivity was observed between subjects in LIRA or CANA/LIRA groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520209
11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, canagliflozin plus liraglutide did not improve beta cell glucose sensitivity more than liraglutide alone.
In plain wordsIn adults with type 2 diabetes, adding canagliflozin to liraglutide did not improve beta cell glucose sensitivity more than liraglutide alone.
Peptide
Liraglutide
Outcome
No significant changeBeta cell glucose sensitivity, combination versus liraglutide alone
Study
n: not reported in source
Comparator
Liraglutide alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
No significant difference in the increase in insulin secretion or beta cell glucose sensitivity was observed between subjects in LIRA or CANA/LIRA groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520210
12HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In adults with type 2 diabetes, improved beta cell glucose sensitivity was the strongest predictor of the HbA1c decrease with each therapy in multivariate regression.
In plain wordsIn adults with type 2 diabetes, better beta cell glucose sensitivity was the strongest predictor of a fall in HbA1c with each treatment.
Peptide
Liraglutide
Outcome
Not applicablePredictor of HbA1c decrease
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In multivariate regression model, improved beta cell glucose sensitivity was the strongest predictor of HbA1c decrease with each therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 45 poorly controlled (HbA1c = 7%-11%) T2DM patients received an oral glucose tolerance test (OGTT) before and after 16 weeks of treatment with: (i) liraglutide (LIRA); (ii) canagliflozin (CANA); (iii) liraglutide plus canagliflozin (CANA/LIRA).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3274520212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT07325435

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

MaryAnn Banerjin = 6021 Dec 2024 to est. 30 Jun 2028

Type 2 Diabetes (T2DM)

Trial page ClinicalTrials.govUpdated 8 Jan 2026

CompletedNot applicableResults postedNCT02324842

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

The University of Texas Health Science Center at San Antonion = 45Nov 2014 to 31 Mar 2019

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Dec 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.